DOSING PROTOCOLS
01. AOD-9604
Protocol Type: Community / Preclinical
Starting Protocol: 300 mcg daily
Standard Protocol: 500 mcg daily
Upper Reported Range: Up to 1 mg daily
Frequency: Once daily
Common Timing: Morning / fasted
Route: Subcutaneous
Typical Cycle: 12-16 weeks
Protocol Structure:
Weeks 1-4: 300 mcg daily
Weeks 5-12: 500 mcg daily
Optional extension: 300-500 mcg daily
02. BAC WATER
Protocol Type: Diluent / Research Use
Dosing Protocol: Not applicable.
Bacteriostatic Water is a diluent rather than an active peptide or research compound.
Research Calculator:
Use the Research Calculator for concentration calculations rather than presenting BAC Water as having a dosing schedule.
03. BPC-157
Protocol Type: Community / Predominantly Preclinical
Starting Protocol: 250 mcg daily
Standard Protocol: 500 mcg daily
Upper Reported Range: 750 mcg daily
Frequency: Once or twice daily
Route: Subcutaneous; other experimental routes are also reported
Typical Cycle: 4-6 weeks
Extended Cycle: Up to approximately 8 weeks
Protocol Structure:
Weeks 1-2: 250 mcg daily
Weeks 3-6: 500 mcg daily
Higher community protocols may divide the daily amount into two administrations.
Protocol Note:
No established FDA-approved human dosing protocol exists.
04. CAGRILINTIDE
Protocol Type: Clinical Research
Frequency: Once weekly
Route: Subcutaneous
Common Research Titration:
Weeks 1-4: 0.25 mg weekly
Weeks 5-8: 0.5 mg weekly
Weeks 9-12: 1.0 mg weekly
Weeks 13-16: 1.7 mg weekly
Week 17+: 2.4 mg weekly
Earlier Phase 2 research also evaluated higher weekly exposures, including doses up to approximately 4.5 mg weekly.
Typical Research Duration:
Long-term clinical studies extending for several months.
Protocol Note:
Cagrilintide remains investigational.
05. CJC-1295 NO DAC + IPAMORELIN
Protocol Type: Combination / Growth-Hormone Axis
Starting Protocol:
CJC-1295 No DAC 100 mcg + Ipamorelin 100 mcg, once daily, commonly before sleep.
Standard Protocol:
CJC-1295 No DAC 100-200 mcg + Ipamorelin 200 mcg, 1-2 times daily.
Upper Community Protocol:
CJC-1295 No DAC 200 mcg + Ipamorelin 300 mcg, up to 2-3 times daily.
Common Timing:
Morning fasted and/or before sleep
Route: Subcutaneous
Typical Cycle: 8-12 weeks
Common Off Period: Approximately 4 weeks
Protocol Note:
The exact CJC-1295 No DAC + Ipamorelin combination does not have an FDA-approved dosing schedule.
06. DSIP
Protocol Type: Community / Experimental
Starting Protocol: 100 mcg
Standard Protocol: 200 mcg
Upper Reported Range: 300 mcg
Frequency: Once daily
Timing: Evening / before sleep
Route: Subcutaneous
Typical Cycle: 2-4 weeks
Protocol Note:
No established modern FDA-approved dosing protocol exists for DSIP.
07. EPITALON / EPITHALON
Protocol Type: Experimental / Limited Human Research
Standard Cycle:
5 mg daily for 20 consecutive days.
Condensed Cycle:
10 mg daily for 10 consecutive days.
Common Timing: Evening
Route: Subcutaneous or intramuscular protocols are reported
Repeat: Approximately 2-3 cycles per year
Cycle Note:
Both schedules equal approximately 100 mg total per cycle; reported cycles are commonly separated by approximately 4-6 months.
08. GHK-CU
Protocol Type: Community / Preclinical Systemic Protocol
Starting Protocol: 1 mg daily
Standard Protocol: 1-1.5 mg daily
Higher Community Protocol: 1.5-2 mg daily
Upper Reported Range: Some community references report doses approaching 3 mg daily
Frequency: Daily
Route: Subcutaneous
Typical Cycle: 4-8 weeks
Common Cycle Options:
Conservative:
1 mg, 5 days on / 2 days off for 4 weeks.
Standard:
1-1.5 mg daily for 4-6 weeks.
Higher:
1.5-2 mg daily for 6-8 weeks.
Protocol Note:
Topical GHK-Cu uses different concentration-based protocols.
09. HUMANIN
Protocol Type: Preclinical / Experimental
Human Dose Status:
No established human therapeutic dose.
Community Research Protocol:
Approximately 0.5 mg per session starting range
Approximately 1 mg per session common research amount
Approximately 2-3 sessions weekly
Route:
Subcutaneous in community research protocols
Typical Cycle:
Short: 4 weeks
Standard: 6-8 weeks
Extended: Up to 12 weeks
Published Preclinical HNG Reference:
4 mg/kg twice weekly, intraperitoneal in animal studies.
Protocol Note:
Humanin and HNG should not be treated as interchangeable without identifying the exact compound.
10. IPAMORELIN
Protocol Type: Community Research / Human Pharmacology Data
Assessment Phase:
Week 1 – 100 mcg daily, usually before sleep.
Titration:
Weeks 2-3 – 200 mcg daily.
Standard Phase:
Weeks 4-8 – 200-300 mcg daily, usually once or divided into two administrations.
Extended Phase:
Weeks 9-12 – 200-300 mcg daily.
Route: Subcutaneous
Typical Cycle: 8-12 weeks
Optional Extended Cycle: Up to approximately 16 weeks
Common Off Period: Approximately 4 weeks
Common Timing: Fasted morning and/or bedtime
11. KISSPEPTIN-10
Protocol Type: Human Research + Experimental Protocols
Lower Pulse Protocol: 50-100 mcg once daily
Standard Research Protocol: 100-200 mcg once daily
Split Protocol: 100 mcg twice daily
Route: Subcutaneous
Typical Community Cycle: Approximately 2-6 weeks
Protocol Note:
Long continuous exposure is generally avoided in research because receptor desensitization/tachyphylaxis can occur.
Kisspeptin-10 and Kisspeptin-54 have different pharmacokinetics and should not be treated as interchangeable.
12. KPV
Protocol Type: Community / Preclinical
Starting Protocol: 200 mcg daily
Standard Protocol: 300-500 mcg daily
Upper Community Range: Up to approximately 1 mg daily
Frequency: Once daily
Route: Subcutaneous or oral research protocols
Typical Cycle: 4-8 weeks
Protocol Note:
Some oral community protocols divide the daily amount into two administrations. No completed human dose-finding study has established an official KPV dose.
13. LL-37
Protocol Type: Community Research / Limited Human Topical Research
Community Injectable Starting Range: 100 mcg daily
Community Injectable Common Range: 100-250 mcg daily
Upper Community Range: Approximately 500 mcg daily
Frequency: Once daily
Route: Subcutaneous
Typical Cycle: 2-4 weeks
Human Clinical Research Context:
Published human wound research used topical LL-37 rather than injected LL-37; reported topical concentrations included approximately 0.5-1.6 mg/mL, typically applied about twice weekly in the studied wound protocols.
Protocol Note:
The injectable schedule is community-derived rather than human-trial validated.
14. MOTS-C
Protocol Type: Community / Predominantly Preclinical
Starting Protocol: 5 mg, 3 times weekly
Standard Protocol: 10 mg, 3 times weekly
Higher Community Protocol: 10 mg, up to 5 times weekly
Common Timing: Morning
Route: Subcutaneous
Typical Cycle: 4-8 weeks
Protocol Note:
No FDA-approved human dosing regimen exists.
15. NAD+
Classification:
Coenzyme rather than peptide
Subcutaneous Protocol:
50 mg starting amount
50-100 mg per session standard
2-3 times weekly
Intramuscular Protocol:
50-100 mg
1-3 times weekly
Intravenous Protocol:
250-500 mg per session standard
Higher clinic protocols: 500-1,000 mg per session
Weekly or every other week depending on protocol
Protocol Note:
There is no single standardized NAD+ dosing schedule across all routes.
16. PT-141 / BREMELANOTIDE
Protocol Type: FDA-Labeled + Community Research
Lower Community Protocol: 0.5 mg
Standard Community Range: 1-1.5 mg
Upper Community Range: Approximately 2 mg
Frequency: As needed
Common Timing: Approximately 45-60 minutes before intended activity
FDA-Labeled Bremelanotide Protocol:
1.75 mg subcutaneous, at least 45 minutes before anticipated sexual activity; maximum one dose within 24 hours; no more than 8 doses per month.
Protocol Note:
The FDA-labeled regimen specifically applies to the Vyleesi pharmaceutical product and its approved population.
17. RETATRUTIDE
Protocol Type: Investigational Human Clinical Research
Frequency: Once weekly
Route: Subcutaneous
Research Titration Example:
Weeks 1-4: 1 mg weekly
Weeks 5-8: 2 mg weekly
Weeks 9-12: 4 mg weekly
Weeks 13-16: 6 mg weekly
Weeks 17-20: 9 mg weekly
Week 21+: up to 12 mg weekly
Phase 2 Alternative Structure:
1 mg → 2 mg → 4 mg → 8 mg → 12 mg
Approximately four weeks between escalation steps.
Studied Target Doses:
4 mg, 9 mg and 12 mg depending on study arm.
Protocol Note:
Retatrutide remains investigational.
18. SELANK
Protocol Type: Experimental / International Research
Starting Protocol: 250 mcg daily
Standard Protocol: 500 mcg daily
Upper Research Range: Approximately 750 mcg daily
Frequency: Once or twice daily
Primary Route: Intranasal
Alternative Research Route: Subcutaneous
Common Timing: Morning / daytime
Typical Cycle: 2-4 weeks
Protocol Note:
Long continuous cycles are less commonly described than short research courses.
19. SEMAGLUTIDE
Protocol Type: FDA-Labeled / Clinical
Frequency: Once weekly
Route: Subcutaneous for injectable protocols
Standard Weekly Escalation:
Weeks 1-4: 0.25 mg weekly
Weeks 5-8: 0.5 mg weekly
Weeks 9-12: 1.0 mg weekly
Weeks 13-16: 1.7 mg weekly
Week 17+: 1.7-2.4 mg weekly depending on clinical context/formulation.
Upper Weight-Management Reference:
2.4 mg weekly
Protocol Note:
The FDA-approved schedule applies to approved semaglutide pharmaceutical formulations.
20. SEMAX
Protocol Type: Experimental / International Human Research
Starting Protocol: 200 mcg daily
Standard Protocol: Approximately 400 mcg daily
Upper Research Range: Approximately 600 mcg daily
Frequency: Once or twice daily
Primary Route: Intranasal
Alternative Research Route: Subcutaneous
Common Timing: Morning and/or early afternoon
Typical Cycle: 2-4 weeks
Protocol Note:
Later-day use is commonly avoided in protocols where stimulation interferes with sleep.
21. SERMORELIN
Protocol Type: Historical Clinical + Community Protocol
Initiation:
Weeks 1-2 – 100 mcg nightly
Standard Titration:
Weeks 3-4 – 200 mcg nightly
Standard Protocol:
200-300 mcg nightly
Upper Community Range:
400-500 mcg nightly
Frequency: Once daily
Timing: Approximately 30-60 minutes before sleep
Route: Subcutaneous
Scheduling Options:
7 days per week
or
5 days on / 2 days off
Typical Cycle:
Approximately 3-6 months
22. SS-31 / ELAMIPRETIDE
Protocol Type: FDA-Labeled + Clinical Research
Also Known As:
SS-31
Elamipretide
MTP-131
Community Research Lower Range: 1 mg daily
Common Community Range: 5 mg daily
Standard Community Research Range: 5-10 mg daily
Higher Reported Research Range: 20 mg daily
Frequency: Once daily
Typical Community Cycle: Approximately 4-8 weeks
FDA-Labeled Elamipretide / Forzinity Reference:
40 mg once daily subcutaneous for the approved Barth syndrome population weighing at least 30 kg; 20 mg once daily for adults with severe renal impairment who are not receiving dialysis.
Protocol Note:
The approved Forzinity protocol is specific to the FDA-approved formulation and indication.
23. SURVODUTIDE
Protocol Type: Investigational Human Clinical Research
Frequency: Once weekly
Route: Subcutaneous
Phase 2 Research Target Doses:
0.6 mg
2.4 mg
3.6 mg
4.8 mg weekly
Escalation Period:
Approximately 20 weeks
Maintenance Period:
Approximately 26 additional weeks
Total Phase 2 Study Duration:
Approximately 46 weeks
Protocol Note:
The 4.8 mg weekly arm represented the highest Phase 2 obesity-study dose. Phase 3 research uses slower and more flexible titration. Survodutide remains investigational.
24. TB-500
Protocol Type: Community Research / Limited Clinical Safety Data
Starting Loading Protocol:
2 mg twice weekly
Standard Loading Protocol:
2-2.5 mg twice weekly
Higher Community Loading Protocol:
Up to approximately 5 mg twice weekly
Loading Duration:
4-6 weeks
Maintenance Protocol:
Approximately 2 mg once weekly
Maintenance Duration:
Approximately 4-8 additional weeks
Route: Subcutaneous
Protocol Note:
The loading/maintenance structure is primarily community-derived rather than an FDA-established protocol.
25. TESAMORELIN
Protocol Type: FDA-Labeled + Research
Frequency: Once daily
Route: Subcutaneous
Research-Vial / Original Phase III Protocol:
2 mg daily, no titration, approximately 26 weeks; extended studies continued for approximately 52 weeks.
Egrifta SV FDA-Labeled Dose:
1.4 mg once daily
Egrifta WR FDA-Labeled Dose:
1.28 mg once daily
Protocol Note:
The formulation matters because Egrifta SV, Egrifta WR and research vials have different concentrations.
26. THYMOSIN ALPHA-1
Protocol Type: International Clinical Protocol
Established International Clinical Reference:
1.6 mg twice weekly, spaced approximately 3-4 days apart
Route: Subcutaneous
Community Research Lower Range:
Approximately 1.5 mg every other day
Standard Community Protocol:
Approximately 1.5 mg daily
Higher Community Reports:
Up to approximately 3 mg daily
Typical Research Cycle:
Approximately 4-12 weeks depending on research context
Protocol Note:
The 1.6 mg twice-weekly schedule has substantially stronger clinical precedent than higher-frequency community protocols.
27. TIRZEPATIDE
Protocol Type: FDA-Labeled / Clinical
Frequency: Once weekly
Route: Subcutaneous
Standard Titration:
Weeks 1-4: 2.5 mg weekly
Weeks 5-8: 5 mg weekly
If additional escalation is required, increase only after at least approximately four weeks at the current dose.
Progression:
7.5 mg → 10 mg → 12.5 mg → 15 mg weekly
Common Maintenance Doses:
5 mg, 10 mg or 15 mg weekly
Maximum FDA-Labeled Weekly Dose:
15 mg weekly
28. TIRZEPATIDE
Protocol Type: FDA-Labeled / Clinical
Frequency: Once weekly
Route: Subcutaneous
Standard Titration:
Weeks 1-4: 2.5 mg weekly
Weeks 5-8: 5 mg weekly
If additional escalation is required, increase only after at least approximately four weeks at the current dose.
Progression:
7.5 mg → 10 mg → 12.5 mg → 15 mg weekly
Common Maintenance Doses:
5 mg, 10 mg or 15 mg weekly
Maximum FDA-Labeled Weekly Dose:
15 mg weekly